The year 2026 marks a significant turning point in the pharmaceutical industry with the patent expiration of seven blockbuster drugs. This presents unique investment opportunities in generic and biosimilar manufacturers, as well as for innovative companies poised to fill market gaps. Understand the financial implications and strategic moves for investors.